Vaccine Therapy for Newly Diagnosed Glioblastoma GBM

ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma

  • Clinical Trial Information

    Trial Contact: Manchola-Orozco, Carolina; Walton, Sherri

    Trial Phone: 321.841.7293 ; 321.841.1907

  • IRB No: S20.035.04

    Protocol Abbrev: ATTAC II

    Principal Investigator: Nicholas G. Avgeropoulos, MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: ATTAC-II

    Treatment: Vaccine plus SOC

    Therapies Involved: Surgery; Radiation ID: NCT02465268

  • Objective

    The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.

  • Key Eligibility

    1. Age ≥ 18 years.
    2. Histopathologically proven newly-diagnosed de novo GBM (secondary GBM not eligible)..
    3. Patient must have undergone definitive surgical resection of tumor with less than 3cm x 3cm residual enhancing tumor in longest perpendicular planes by MRI.